Senex Biotechnology. Inc.

Exciting update from Senex! ?? The Company has been granted a Notice of Allowance by the Japanese Patent Office for SNX631-6, our clinical candidate. This compound, a robust inhibitor of CDK8/19, has shown remarkable potency, specificity, and tolerance. The patent highlights its application in breast and ovarian cancer, aligning with our commitment to advancing women's health. This milestone builds on our recent focus on CDK8/19 inhibition in Triple Negative Breast cancer, as featured in a publication by PNAS. Additionally, we are thrilled to announce a new STTR grant aimed at developing an intraperitoneal formulation of SNX631-6 for metastatic ovarian cancer treatment. ?? Learn more about our progress: - PNAS publication: [Link to the article](https://lnkd.in/e7bHn4Y2) - STTR grant details: [Read more](https://lnkd.in/dC_FwXcJ) Stay tuned for more updates as we continue to drive innovation in cancer treatment! ?? #Senex #CancerResearch #Innovation

More exciting news for Senex as we secure a grant to advance our work in women's health. Metastatic ovarian cancer (OC) stands as a significant health challenge, ranking as the second most common gynecological malignancy with grave implications. The grant will support the development of a novel intraperitoneal injection formulation of SNX631-6, Senex's pluripotent CDK8/19 inhibitor, as a treatment for OC. This initiative builds upon the recent PNAS publication emphasizing the crucial role of CDK8/19 and the efficacy of SNX631-6 in treating triple-negative breast cancer (TNBC) and other breast cancer subtypes. (Mediator Kinase Inhibitors Suppress Triple-Negative Breast Cancer Growth and Extend Tumor Suppression by mTOR and AKT Inhibitors?, PNAS 2024. https://lnkd.in/e7bHn4Y2. We are looking forward to advancing SNX631-6 into clinical development in the upcoming year.

A new, groundbreaking publication by Senex scientists in the PNAS sheds light on the critical role of CDK8/19 treatment in various types of breast cancer, including triple-negative. The research, a collaboration between Senex and esteemed institutions like the University of South Carolina and the Medical University of South Carolina, represents years of dedicated effort. Senex's advanced clinical candidate, SNX631-6, emerges as a promising CDK8/19 inhibitor. With remarkable potency, specificity, and favorable oral bioavailability and pharmacokinetics, SNX631-6 stands out as a potential game-changer in cancer treatment. The company aims to commence pivotal first-in-human trials in 2026, marking a significant step towards combating breast cancer effectively.

I am very pleased to announce that Senex has received a Notice of Allowance from the European patent office for SNX631-6 composition of matter and use as treatment for cancer. This patent, along with the US patent issued in 2023, provides broad protection for our clinical candidate. The patent application is under review in multiple other countries around the world.

Senex scientists publish paper in Journal of Clinical Investigation describing the importance of CDK8/19 treatment in castration resistant prostate cancer. This paper reports on years of work by the Senex team and their colleagues at the University of South Carolina and the Medical University of South Carolina. The Company's clinical candidate, SNX631-6, is a highly potent, specific, well-tolerated CDK8/19 inhibitor with excellent oral bioavailability and pharmacokinetics. Senex hopes to initiate first-in-human studies in 2025.

Senex scientists publish paper in Journal of Clinical Investigation describing the importance of CDK8/19 treatment in castration resistant prostate cancer. This paper reports on years of work by the Senex team and their colleagues at the University of South Carolina and the Medical University of South Carolina. The Company's clinical candidate, SNX631-6, is a highly potent, specific, well-tolerated CDK8/19 inhibitor with excellent oral bioavailability and pharmacokinetics. Senex hopes to initiate first-in-human studies in 2025.